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Dear Editor
The Pitfalls of FeNO Testing
The article on fractional exhaled nitric oxide (FeNO)
as a marker of airway inflammation by Mitsuru Mu-
nakata1 correctly highlights the practical problems
clinicians face when interpreting the FeNO results in
the clinic due to (a) large variations in the ‘normal’
ranges of FeNO in children and adults (usual upper
limit of reference range 27-57 parts per billion by vol-
ume [ppbv] excluding asthma and atopy but still de-
pendent on gender)2; (b) different technologies in
use to measure the FeNO levels such as with the
electrochemical sensor NIOX MINOⓇ portable hand-
held NO analyzer (Aerocrine AB, Stockholm, Swe-
den) assuming a constant flow rate of 50 mls, or the
more sensitive and NO specific but labour-intensive
chemiluminescence method and emerging technol-
ogy such as the quantum cascade laser ( QSL )
method reaching detection sensitivity at single part
per billion by volume (ppbv, 1 : 10−9).3 Of note, The
National Health and Nutrition Examination Survey re-
port just published data on 13,275 participants aged
six to 80 years who had their FeNO measured using
the chemiluminescence method also show the large
variations that remain to be explained,4 apart from
gender, atopy, smoking and paranasal sinus inflam-
mation that are known factors to affect results.
One group of clinical conditions where persistent
low values <25 ppbv in adults and <20 ppbv in chil-
dren are extremely significant is ciliary problems, es-
pecially primary ciliary dyskinesia (PCD) where low
FeNO is reportedly highly sensitive 97% and specific
90% for this condition.5 A diagnosis of airway inflam-
mation ( eosinophilic or otherwise ) is unlikely if
FeNO levels are always low and ciliary dyskinesias
especially if bronchiectasis if present should be con-
sidered. It remains to be established whether local in-
ducible nitric oxide synthase ( iNOS) is affected in
PCD as a generalized disorder of NO handling has
not been demonstrated.6 Clinicians therefore need to
know the limitations of biologic tests and follow up
persistently low FeNO levels and question the diag-
nosis of airway inflammation in these patients.
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